Fig. 2
From: 2015 Japanese Society for Dialysis Therapy: Guidelines for Renal Anemia in Chronic Kidney Disease
Secondary analysis of the Correction of Hemoglobin and Outcomes in Renal Insufficiency trial: erythropoiesis-stimulating agent dose and prognosis. Status of the achievement of target hemoglobin (Hb) level, incidence of events, and erythropoiesis-stimulating agent (ESA) dose of the normalized Hb group 4 and 9Â months after the start of ESA administration (cited from [9], partially revised)